Last reviewed · How we verify
camrelizumab； famitinib malate
Camrelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immune response.
Camrelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immune response. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Multiple myeloma.
At a glance
| Generic name | camrelizumab； famitinib malate |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the PD-1/PD-L1 interaction, camrelizumab allows T-cells to recognize and attack cancer cells more effectively. This mechanism is thought to be responsible for its anti-tumor activity. Camrelizumab has been shown to be effective in treating various types of cancer, including non-small cell lung cancer and multiple myeloma.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
- Anorexia
- Weight loss
Key clinical trials
- A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer (PHASE2)
- Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer (PHASE3)
- A Study of SHR-1802 in Patients With Advanced Solid Tumor (PHASE2)
- A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC (PHASE3)
- A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients (PHASE2)
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer (PHASE3)
- Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors (PHASE2)
- A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- camrelizumab； famitinib malate CI brief — competitive landscape report
- camrelizumab； famitinib malate updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI